Literature DB >> 20600935

In vitro evolution and analysis of HIV-1 LTR-specific recombinases.

Frank Buchholz1, Joachim Hauber.   

Abstract

Current antiretroviral therapies would greatly benefit from the concurrent removal of integrated HIV-1 proviral DNA from the patient's cells. In this review, we describe an experimental strategy that allowed the engineering and functional analysis of a HIV-1 LTR-specific recombinase (Tre-recombinase). We furthermore provide protocols that are utilized for the investigation of Tre's antiretroviral activity in infected tissue cultures as well as in infected humanized Rag2(-/-)γc(-/-) mice. Copyright Â
© 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20600935     DOI： 10.1016/j.ymeth.2010.06.014

Source DB:  PubMed          Journal:  Methods        ISSN： 1046-2023            Impact factor:   3.608


  16 in total

1.  Directed evolution of a recombinase that excises the provirus of most HIV-1 primary isolates with high specificity.

Authors:  Janet Karpinski; Ilona Hauber; Jan Chemnitz; Carola Schäfer; Maciej Paszkowski-Rogacz; Deboyoti Chakraborty; Niklas Beschorner; Helga Hofmann-Sieber; Ulrike C Lange; Adam Grundhoff; Karl Hackmann; Evelin Schrock; Josephine Abi-Ghanem; M Teresa Pisabarro; Vineeth Surendranath; Axel Schambach; Christoph Lindner; Jan van Lunzen; Joachim Hauber; Frank Buchholz
Journal:  Nat Biotechnol       Date:  2016-02-22       Impact factor: 54.908

Review 2.  Novel AIDS therapies based on gene editing.

Authors:  Kamel Khalili; Martyn K White; Jeffrey M Jacobson
Journal:  Cell Mol Life Sci       Date:  2017-02-16       Impact factor: 9.261

Review 3.  The therapeutic application of CRISPR/Cas9 technologies for HIV.

Authors:  Sheena Saayman; Stuart A Ali; Kevin V Morris; Marc S Weinberg
Journal:  Expert Opin Biol Ther       Date:  2015-04-12       Impact factor: 4.388

Review 4.  DNA cleavage enzymes for treatment of persistent viral infections: recent advances and the pathway forward.

Authors:  Nicholas D Weber; Martine Aubert; Chung H Dang; Daniel Stone; Keith R Jerome
Journal:  Virology       Date:  2014-01-31       Impact factor: 3.616

Review 5.  Targeted DNA mutagenesis for the cure of chronic viral infections.

Authors:  Joshua T Schiffer; Martine Aubert; Nicholas D Weber; Esther Mintzer; Daniel Stone; Keith R Jerome
Journal:  J Virol       Date:  2012-06-20       Impact factor: 5.103

6.  Crystal structure of an engineered, HIV-specific recombinase for removal of integrated proviral DNA.

Authors:  Gretchen Meinke; Janet Karpinski; Frank Buchholz; Andrew Bohm
Journal:  Nucleic Acids Res       Date:  2017-09-19       Impact factor: 16.971

7.  Highly significant antiviral activity of HIV-1 LTR-specific tre-recombinase in humanized mice.

Authors:  Ilona Hauber; Helga Hofmann-Sieber; Jan Chemnitz; Danilo Dubrau; Janet Chusainow; Rolf Stucka; Philip Hartjen; Axel Schambach; Patrick Ziegler; Karl Hackmann; Evelin Schröck; Udo Schumacher; Christoph Lindner; Adam Grundhoff; Christopher Baum; Markus G Manz; Frank Buchholz; Joachim Hauber
Journal:  PLoS Pathog       Date:  2013-09-26       Impact factor: 6.823

8.  Vika/vox, a novel efficient and specific Cre/loxP-like site-specific recombination system.

Authors:  Madina Karimova; Josephine Abi-Ghanem; Nicolas Berger; Vineeth Surendranath; Maria Teresa Pisabarro; Frank Buchholz
Journal:  Nucleic Acids Res       Date:  2012-11-09       Impact factor: 16.971

9.  Excision of HIV-1 proviral DNA by recombinant cell permeable tre-recombinase.

Authors:  Lakshmikanth Mariyanna; Poornima Priyadarshini; Helga Hofmann-Sieber; Marcel Krepstakies; Nicole Walz; Adam Grundhoff; Frank Buchholz; Eberhard Hildt; Joachim Hauber
Journal:  PLoS One       Date:  2012-02-13       Impact factor: 3.240

10.  RNA interference approaches for treatment of HIV-1 infection.

Authors:  Maggie L Bobbin; John C Burnett; John J Rossi
Journal:  Genome Med       Date:  2015-05-28       Impact factor: 11.117
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.